SCHEDULE 13G/A: BB Biotech AG and Subsidiary Maintain 5.0% Stake in Esperion Therapeutics
Beneficial Ownership Report
BB Biotech AG and its wholly-owned subsidiary, Biotech Target N.V., have reported a continued beneficial ownership of 5.0% in Esperion Therapeutics, Inc. common stock as of December 31, 2024.
Summary
- BB Biotech AG, on behalf of its wholly-owned subsidiary Biotech Target N.V., has filed an Amendment No. 12 to Schedule 13G regarding its beneficial ownership in Esperion Therapeutics, Inc.
- As of December 31, 2024, the reporting persons collectively beneficially own 9,944,064 shares of Esperion Therapeutics, Inc. common stock.
- This aggregate amount represents 5.0% of the class of common stock.
- Both BB Biotech AG (Switzerland) and Biotech Target N.V. (Curacao) share voting and dispositive power over all 9,944,064 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, consistent with a passive investment.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) reporting beneficial ownership, providing factual information without expressing positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Esperion Therapeutics, Inc.'s future performance or strategic direction, as it is a beneficial ownership report.
Industry Context
Esperion Therapeutics, Inc. operates in the pharmaceutical and biotechnology industry, focusing on developing and commercializing therapies for cardiovascular and metabolic diseases. This filing indicates a continued significant passive investment by a biotech-focused investment firm.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holding by BB Biotech AG and its subsidiary, confirming their passive investment stance.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date). |
| 02/12/2025 | Date the Schedule 13G Amendment No. 12 was signed and filed. |
Keywords
Esperion Therapeutics, BB Biotech AG, Biotech Target N.V., Schedule 13G, beneficial ownership, common stock, pharmaceutical, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.